• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·BNYN
Share

Banyan Corp. Stocks

$ 0Last Updated 31.07.2026

Issuer Rating

Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

$ 286042

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Banyan Corp., operating through its subsidiaries, focuses on franchising chiropractic clinics throughout North America. The company provides extensive support to its franchisees and licensees, including specialized practice development training and assistance tailored for chiropractors. Beyond its franchising activities, Banyan delivers vital diagnostic testing services. A key offering is Nerve Conduction Velocity (NCV) testing, which is administered to patients via healthcare professionals such as doctors and chiropractors. This NCV testing is instrumental in evaluating the transmission of nerve impulses, identifying irregularities within the nervous system, and supplying objective data to substantiate treatment expenses for patients and their insurance providers. Furthermore, Banyan manufactures and markets its proprietary VT3000, an advanced nerve testing system. This system is engineered for the precise diagnosis of neuropathies – conditions affecting the peripheral nerves and spinal regions – alongside nerve irritation and other forms of nervous system damage in patients. Established in 1978, Banyan Corp. maintains its headquarters in Beverly Hills, California.

Company Valuation

Greatly undervalued
7/7

Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.08.2026 23:29

Shares of Cloud Giants Soared: Microsoft and Amazon Reassured Investors

03.08.2026 22:46

Earnings Reports from Palantir, SpaceX, and AMD Will Be a "Real-World Test" for the AI Rally — Saxo Bank

03.08.2026 22:30

The new "Spider-Man" brought AMC theaters record box office receipts in its 106-year history

03.08.2026 21:58

Aperol sales have fallen in the U.S. What does this mean for investors?

03.08.2026 20:58

Amazon has joined the "club" of companies with a market capitalization of more than $3 trillion. There are only five of them.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026